

Contents lists available at [ScienceDirect](http://ScienceDirect.com)

EBioMedicine

journal homepage: [www.ebiomedicine.com](http://www.ebiomedicine.com)

## Research Article

## Cation Homeostasis in Red Cells From Patients With Sickle Cell Disease Heterologous for HbS and HbC (HbSC Genotype)

A. Hannemann<sup>a</sup>, D.C. Rees<sup>b</sup>, S. Tewari<sup>b</sup>, J.S. Gibson<sup>a,\*</sup><sup>a</sup> Department of Veterinary Medicine, University of Cambridge, Madingley Road, Cambridge CB3 0ES, UK<sup>b</sup> Department of Paediatric Haematology, King's College London School of Medicine, King's College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK

## ARTICLE INFO

## Article history:

Received 31 July 2015

Received in revised form 7 September 2015

Accepted 15 September 2015

Available online 18 September 2015

## Keywords:

Sickle cell disease

HbSC

Red cells

Potassium permeability

KCl cotransport

## ABSTRACT

Sickle cell disease (SCD) in patients of HbSC genotype is considered similar, albeit milder, to that in homozygous HbSS individuals – but with little justification. In SCD, elevated red cell cation permeability is critical as increased solute loss causes dehydration and encourages sickling. Recently, we showed that the KCl cotransporter (KCC) activity in red cells from HbSC patients correlated significantly with disease severity, but that in HbSS patients did not. Two transporters involved in red cell dehydration, the conductive channels  $P_{\text{sickle}}$  and the Gardos channel, behaved similarly in red cells from the two genotypes, but were significantly less active in HbSC patients. By contrast, KCC activity was quantitatively greater in HbSC red cells. Results suggest that KCC is likely to have greater involvement in red cell dehydration in HbSC patients, which could explain its association with disease severity in this genotype. This work supports the hypothesis that SCD in HbSC patients is a distinct disease entity to that in HbSS patients. Results suggest the possibility of designing specific treatments of particular benefit to HbSC patients and a rationale for the development of prognostic markers, to inform early treatment of children likely to develop more severe complications of the disease.

© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

Sickle cell disease (SCD) is one of the commonest severe inherited disorders affecting millions of people worldwide (Piel et al., 2013). Complications of the disease arise from the presence in patients' red cells of the abnormal haemoglobin (Hb), HbS, which has a single amino acid substitution compared to normal adult Hb, HbA. In HbS, valine replaces glutamic acid in the 6th codon of the  $\beta$  chain, with loss of a negative charge (Bunn and Forget, 1986). On deoxygenation, this substitution allows neighbouring molecules of HbS to adhere, forming rigid polymers which distort the shape of the red cell. The complications of SCD all follow from polymerisation of HbS, although in many cases details of the pathogenesis remain unclear.

About two-thirds of SCD patients are homozygous for HbS (HbSS genotype, or disease, sometimes referred to as sickle cell anaemia, SCA) (Rees et al., 2010). Co-inheritance of a second abnormal Hb, HbC, in which lysine replaces glutamic acid at the same position of the  $\beta$  chain, along with HbS produces the heterologous HbSC genotype (HbSC disease) (Nagel and Lawrence, 1991; Nagel and Steinberg, 2001). HbSC individuals account for about one-third of SCD patients (Nagel and Steinberg, 2001) and thereby represent a sizeable patient cohort. The vast majority of laboratory and clinical studies on SCD,


however, including those on red cell cation homeostasis, have been carried out on HbSS patients, with HbSC patients being largely and unjustifiably neglected.

Both HbSS and HbSC disease have profound clinical impact, although those homozygous for HbC (HbCC) are largely asymptomatic (Nagel and Steinberg, 2001). Complications are multiple including chronic anaemia, pain and organ dysfunction with signs dependent on the identity of the affected organ – stroke, acute chest syndrome, nephropathy, osteonecrosis, dactylitis, etc. (Rees et al., 2010; Steinberg et al., 2001; Nagel and Platt, 2001). Between individuals, clinical severity is markedly heterogeneous, with the health of some patients being severely compromised, whilst others present with a less severe disease or even a subclinical course. In many cases it is not understood why. Generally, HbSC disease is milder, though it still presents with significant morbidity (Platt et al., 1991; Nagel et al., 2003). For example, life expectancy of HbSC individuals is markedly reduced (Platt et al., 1994), and some complications of SCD, like proliferative retinopathy (Condon and Serjeant, 1970), are over-represented in HbSC patients.

Intracellular cation homeostasis in red cells is maintained mainly by active movement of  $\text{Na}^+$  and  $\text{K}^+$  via the ATP-driven  $\text{Na}^+/\text{K}^+$ -pump coupled with a relatively low passive permeability through various transport pathways. Together these set intracellular  $[\text{K}^+]$  at about 100 mM and  $\text{Na}^+$  at about 15 mM (Joyce, 1958). A major feature of red cells from SCD patients, however, is their abnormally high cation permeability. This characteristic is important, as it causes red cells to

\* Corresponding author.

E-mail address: [jsg1001@cam.ac.uk](mailto:jsg1001@cam.ac.uk) (J.S. Gibson).



**Fig. 1.** A schematic diagram summarising the main cation pathways involved in solute loss from red cells in patients with sickle cell disease (SCD). In deoxygenated red cells (right), HbS polymerises causing morphological sickling and activation of (i)  $P_{\text{sickle}}$ , a deoxygenation-induced cation conductance. Its main effect is to allow entry of  $\text{Ca}^{2+}$  which activates a second transport pathway, (ii) the  $\text{Ca}^{2+}$ -activated  $\text{K}^+$  channel or Gardos channel, which mediates conductive  $\text{K}^+$  loss at high rates. In oxygenated red cells (left),  $P_{\text{sickle}}$  and the Gardos channel are inactive. A third transport pathway, (iii) the KCl cotransporter (KCC) mediates obligatorily coupled efflux of  $\text{K}^+$  and  $\text{Cl}^-$ . It is present at higher activities in HbS-containing red cells, compared to those from normal (HbAA) individuals. Activity is further enhanced by low pH, swelling and urea. KCC may remain active in deoxygenated sickle cells, with  $\text{Mg}^{2+}$  loss via  $P_{\text{sickle}}$ , further increasing its activity. The relative importance of these pathways in red cells from HbSC and HbSS patients appears to differ which may be important in pathogenesis.

lose intracellular solutes and shrink, thus elevating the intracellular concentration of HbS ([HbS]). As the lag time to polymerisation of deoxygenated HbS is inversely proportional to a very high power of [HbS] (Eaton and Hofrichter, 1987), any shrinkage markedly increases the likelihood of polymerisation as red cells traverse hypoxic regions of the circulation. Considerable effort has been expended on investigating this high cation permeability (Tosteson et al., 1952; Joiner et al., 1993; Gibson and Ellory, 2002; Lew and Bookchin, 2005), and designing potential inhibitors (eg Stocker et al., 2003), but studies are restricted almost exclusively to red cells from HbS patients.

Three main transport systems are involved in solute loss and red cell dehydration (summarised in Fig. 1: Lew and Bookchin, 2005): the deoxygenation-induced cation conductance (sometimes termed  $P_{\text{sickle}}$ ), the  $\text{Ca}^{2+}$ -activated  $\text{K}^+$  channel (or Gardos channel) and the KCl cotransporter (KCC).  $P_{\text{sickle}}$  is activated by deoxygenation and red cell shape change (Tosteson, 1955; Mohandas et al., 1986; Joiner, 1993). It allows entry of  $\text{Ca}^{2+}$  (Rhoda et al., 1990) which may then activate the third transporter (Lew et al., 1997), the Gardos channel, with conductive  $\text{K}^+$  loss at high rates, and  $\text{Cl}^-$  following separately through separate anion channels. KCC mediates coupled movements of  $\text{K}^+$  and  $\text{Cl}^-$  (Ellory et al., 1982; Lauf et al., 1992; Gillen et al., 1996). Its activity is abnormally elevated in red cells from HbSS patients (Brugnara et al., 1986; Crable et al., 2005), and it also responds differently to modulatory stimuli such as  $\text{O}_2$  tension (Gibson et al., 1998), when compared to red cells from normal HbAA individuals. It may also be further stimulated by  $\text{Mg}^{2+}$  depletion via  $P_{\text{sickle}}$  (Ortiz et al., 1990; Delpire and Lauf, 1991). As noted above, with the exception of a few studies involving a handful of HbSC patients (Canessa et al., 1986), our understanding of these systems comes from work on red cells from SCA patients. The behaviour of red cells from HbSC patients and management of disease is largely extrapolated from these studies on HbSS - but this may not be justified.

Our recent study comparing clinical parameters and  $\text{K}^+$  transport in red cells from HbSS and HbSC patients indicated significant differences between the two genotypes (Rees et al., 2015). In particular, KCC activity was higher in HbSC patients with more severe forms of SCD (Rees et al., 2015), whilst the same was not true for KCC activity in red cells from HbSS patients. These findings, along with differences in clinical pathology, support the hypothesis that HbSC disease is a distinct clinical entity. Since changes in red cell membrane permeability represent an early event in SCD pathogenesis, with a direct association with HbS polymerisation, further work on membrane transport in red cells from HbSC patients is an imperative. In this report, we characterise more fully the behaviour of the main  $\text{K}^+$  transport systems in red cells from HbSC patients and highlight important differences in comparison with red cells from patients with SCA.

## 2. Materials and Methods

### 2.1. Chemicals

Bumetanide, 3-[N-morpholino] propane sulphonic acid (MOPS), nystatin, ouabain, OptiPrep and salts were purchased from Sigma Chemical Co. (Poole, Dorset, UK). Clotrimazole and 4-(2-hydroxyethyl)-1-piperazine ethane sulphonic acid (HEPES) were purchased from Calbiochem (Nottingham, UK).  $^{86}\text{Rb}^+$  was supplied by Perkin Elmer (Beaconsfield, UK).

### 2.2. Sample Collection and Handling

Blood samples were taken for routine tests according to clinical indications from patients at King's College Hospital, homozygous HbSS or heterozygous HbSC for sickle cell disease (SCD), using the anticoagulant EDTA. During the course of this study, around two hundred patients of the HbSC genotype attended the sickle cell clinics at KCH, compared to about four hundred of HbSS genotype. Samples were kept at 4 °C until use within 48 h. The study was approved by the National Research Ethics Committee London-East (reference 11/LO/0065). For some experiments, after routine haematological testing, discarded and anonymised blood was analysed, under the approval of the local ethics committee. All research was conducted in accordance with the Helsinki Declaration of 1975, as revised in 2008.

### 2.3. Solutions and Tonometry

The standard saline (Cl-MBS) comprised (in mM): 145 NaCl, 1.1  $\text{CaCl}_2$ , 5 glucose and 10 MOPS, (pH 7.4 at 37 °C;  $290 \pm 5$  mOsm.kg $^{-1}$   $\text{H}_2\text{O}$ ). For experiments in which  $\text{Cl}^-$  dependence of  $\text{K}^+$  influx was examined,  $\text{NO}_3^-$  containing salts replaced those containing  $\text{Cl}^-$  (N-MBS). The wash solution to remove unincorporated  $^{86}\text{Rb}^+$  comprised isotonic  $\text{MgCl}_2$  (107 mM), buffered with MOPS (10 mM), pH 7.4 at 4 °C (Mg-MBS). Stock solutions of bumetanide (10 mM), ouabain (10 mM) and clotrimazole (CLT; 5 mM) were prepared in 100 mM Tris base, distilled water and DMSO, respectively. In most experiments whole blood was washed five times in N-MBS to remove  $\text{Cl}^-$ , plasma and buffy coat. Red cell suspensions at 20% haematocrit (Hct) in N-MBS were placed in tonometers (Eschweiler, Kiel, Germany) flushed with warm, humidified gas mixtures for 20 min at 37 °C to equilibrate at the requisite  $\text{O}_2$  tension before flux measurements and red cell shape analysis (Speake et al., 1997). Gas mixtures were made using a Wösthoff gas mixing pump (Speake et al., 1997). For flux measurements, red cell suspensions were then diluted ten-fold into flux tubes, still equilibrated at the required  $\text{O}_2$  tension. To analyse red cell shape, aliquots of cells were placed

in saline containing 0.3% glutaraldehyde before examination under light microscopy.

#### 2.4. $K^+$ Flux Measurements

To determine the activity of the  $K^+$  transport pathways,  $K^+$  influx was measured at 37 °C using  $^{86}Rb^+$  as a congener for  $K^+$  (Dunham and Ellory, 1981; Hannemann et al., 2011). Red cells were taken from tonometers and diluted 10-fold into saline, pre-equilibrated at the appropriate  $O_2$  tension, and, unless otherwise stated, at 260 mOsm.kg<sup>-1</sup> and pH 7.  $^{86}Rb^+$  was added in 150 mM KNO<sub>3</sub> to give a final [ $K^+$ ] of 7.5 mM. Typically, three flux conditions were used: (i) Cl-MBS, (ii) Cl-MBS with clotrimazole and (iii) N-MBS with clotrimazole. Ouabain (0.1 mM) and bumetanide (0.01 mM) were present in all experiments to obviate any  $K^+$  transport through the  $Na^+/K^+$  pump and the  $Na^+-K^+-2Cl^-$  cotransporter, respectively. After incubation with radioisotope for 10 min, red cells were washed five times in ice-cold Mg-MBS wash solution to remove extracellular  $^{86}Rb^+$ . Following the final wash, the cell pellet was lysed with Triton X-100 (0.1%) and protein precipitated with trichloroacetic acid (5%). Activity was then measured as Čerenkov radiation by liquid scintillation (Packard Tri-carb 2100TR).  $P_{sickle}$  was assayed as the deoxygenation-induced, clotrimazole-independent  $K^+$  influx measured in the absence of  $Cl^-$  (condition iii); Gardos channel activity as the CLT-sensitive (0.005 mM)  $K^+$  influx (using conditions i & ii); and KCC activity was assayed as  $Cl^-$  dependent  $K^+$  influx (using flux conditions ii & iii). For CLT, dissolved in DMSO, appropriate controls were all treated with the same concentration of solvent (0.1% final). Either microhaematocrit determination or the cyanohaemoglobin method was used to measure the Hct with appropriate samples for this taken before the start of each experiment.

#### 2.5. Density Separation

Whole blood was washed three-times in HEPES-buffered saline (HBS, comprising in mM: 140 NaCl, 5 KCl, 0.15 MgCl<sub>2</sub>, 10 HEPES, pH 7.4 at room temperature) to remove plasma and buffy coat. Red cells were separated according to density into light, intermediate and dense fractions by centrifugation on gradients of OptiPrep. Stock solution of OptiPrep (60% w/v iodixanol) was diluted to 40% w/v in 3xHBS (HBS containing 30 mM HEPES) before diluting further in HBS to produce the desired densities. Densities used depended on the blood samples and were  $<1.095 \pm 0.001$  and  $>1.098 \pm 0.001$  g.ml<sup>-1</sup> for HbSC and  $<1.089 \pm 0.001$  and  $>1.093 \pm 0.002$  g.ml<sup>-1</sup> for HbSS to recover the light and dense fraction, respectively. 150  $\mu$ l of loosely packed red cells were layered over 0.4 ml gradient in 1.5 ml tubes and centrifuged at 700 g at 10 °C for 5 min (Denley BR401 bench-top centrifuge, swing-out rotor). Fractions were isolated, washed in HBS and, where necessary, separated on a different gradient in order to obtain the light, intermediate and dense fraction. Light and dense cell fractions were divided into two, with half kept as controls and half treated subsequently with nystatin.

#### 2.6. Nystatin Treatment

Density separated red cells were washed three-times in HK-HBS (comprising in mM: 135 KCl, 10 NaCl, 10 glucose, 10 HEPES, pH 7.4 at RT;  $290 \pm 5$  mOsm.kg<sup>-1</sup>) before treatment on ice for 45 min with nystatin (0.1 mg.ml<sup>-1</sup>) at 5% Hct in HK-HBS containing 25 mM sucrose. Nystatin was then removed using seven washes with HK-HBS containing sucrose (25 mM) and bovine serum albumin (1 mg.ml<sup>-1</sup>) at room temperature. Prior to  $K^+$  influx measurements, nystatin-treated and untreated red cells were washed four times with ice-cold N-MBS, adjusted to 20% Hct. They were then diluted ten-fold into saline for measurement of  $K^+$  influx, as described above.


#### 2.7. Statistics

Results are presented as means  $\pm$  S.E.M. of n observations in red cell samples taken from different individuals. Where appropriate, comparisons were made using unpaired (Figs. 3–5, 7) and paired (Fig. 8) two-tailed Student's t-tests. Correlations were made using the Pearson correlation test. The level of significance used was  $p < 0.05$ .

### 3. Results

#### 3.1. Sickling and Conductive $K^+$ Transport in Red Cells From HbSC and HbSS Patients

Sickling and conductive  $K^+$  transport were measured in air and across the physiological range of  $O_2$  tensions in red cells from HbSC patients. Morphological shape change became apparent as  $O_2$  tension was reduced to about the  $P_{50}$  of Hb. Several aspects of  $K^+$  transport in HbSC cells were also sensitive to  $O_2$  tension (Fig. 2a). At arterial  $O_2$  tensions, the deoxygenation-induced cation conductance, or  $P_{sickle}$ , and the Gardos channel showed low activities. As for sickling, these increased as  $O_2$  tensions were reduced to levels at which Hb becomes deoxygenated. Activities of both were maximal at the lowest  $O_2$  tensions and also correlated with degree of cell sickling (Fig. 2b & c; Pearson



**Fig. 2.** Conductive  $K^+$  pathways and sickling in red cells from HbSC patients. Red cells (20% haematocrit, Hct) were equilibrated in Eschweiler tonometers at the indicated oxygen tension for 20 min. Red cell aliquots were then fixed in 0.3% glutaraldehyde and percentage sickling assessed by light microscopy. Further aliquots were diluted ten-fold into test tubes for measurement of  $K^+$  influx (given as  $mmol\ K^+.(l\ cells.h^{-1})$ ).  $P_{sickle}$  activity is defined as the deoxygenation-induced  $K^+$  influx in  $Cl^-$  free saline in the presence of ouabain (100  $\mu$ M), bumetanide (10  $\mu$ M) and clotrimazole (CLT; 5  $\mu$ M), and the Gardos channel activity as the CLT-sensitive  $K^+$  influx in the presence of ouabain and bumetanide. (a) Oxygen dependence of sickling,  $P_{sickle}$  and Gardos channel. Data are presented as means  $\pm$  S.E.M.,  $n = 4-8$ . (b, c) Pearson correlation of  $P_{sickle}$  and Gardos channel activities with % sickling. Correlations were  $r = 0.302$  ( $p < 0.01$ ) for  $P_{sickle}$  and  $r = 0.305$  ( $p < 0.01$ ) for the Gardos channel.



correlation coefficient  $r = 0.302$ ,  $p = 0.0014$  for  $P_{\text{sickle}}$ , and  $r = 0.305$ ,  $p = 0.0012$  for Gardos channel).

Sickling and the activities of  $K^+$  transport were compared in red cells from HbSC and HbSS patients in more detail. In oxygenated conditions, the percentage of sickled red cells was  $8.4 \pm 1.1\%$  and  $0.2 \pm 0.04\%$  (Fig. 3b) in HbSS and HbSC patients, respectively. The higher values in patients with SCA were presumably due to the presence of irreversibly sickled cells (ISCs) which were observed in oxygenated HbSS samples but were absent in those from HbSC individuals. In both genotypes, sickling was observed in around 80% of red cells on deoxygenation (Fig. 3b).

The residual  $K^+$  influx in  $Cl^-$  free media was also measured in both oxygenated and deoxygenated cells in the presence of ouabain and bumetanide (Fig. 3a). At both  $O_2$  tensions, residual  $K^+$  influx was lower in red cells from HbSC patients compared to those from HbSS patients. ISCs probably account for the higher levels of residual  $K^+$  influx in oxygenated red cells from HbSS patients (Fig. 3a). Levels in red cells from both genotypes were increased by deoxygenation, as  $P_{\text{sickle}}$  becomes activated, more so in the latter than the former ( $0.99 \pm 0.09 \text{ mmol} \cdot (\text{l cell} \cdot \text{h})^{-1}$ ,  $n = 40$ , in red cells from HbSS patients cf.  $0.34 \pm 0.02 \text{ mmol} \cdot (\text{l cell} \cdot \text{h})^{-1}$ ,  $n = 110$ , in those from HbSC individuals;  $p < 0.0001$ ).

Gardos channel activity was also measured in fully oxygenated and deoxygenated red cells (Fig. 4a). As for the residual  $K^+$  influx, it showed higher levels in deoxygenated red cells from HbSS patients compared to those from HbSC individuals ( $4.63 \pm 0.51 \text{ mmol} \cdot (\text{l cell} \cdot \text{h})^{-1}$ ,  $n = 40$ , cf.  $1.57 \pm 0.12 \text{ mmol} \cdot (\text{l cell} \cdot \text{h})^{-1}$ ,  $n = 110$ ;  $p < 0.0001$ ). For both genotypes, Gardos channel activity correlated positively with that of  $P_{\text{sickle}}$  (Fig. 4b:  $r = 0.433$ ,  $p < 0.0001$  for HbSC;  $r = 0.530$ ,  $p = 0.0004$ , for HbSS), although activities of both were higher in red cells from homozygous HbSS patients compared to those from heterologous HbSC individuals.

At intermediate oxygen tensions, further differences between red cells from HbSC and HbSS patients were apparent (Fig. 5). In both genotypes, full deoxygenation elicits maximal levels of sickling, and activities of  $P_{\text{sickle}}$  and the Gardos channel. At an oxygen tension of 20 mmHg, just below the  $P_{50}$  for Hb, all three parameters were significantly higher in red cells from HbSS patients. A similar trend was also observed at an oxygen tension of 40 mmHg, just above the  $P_{50}$  for Hb. These findings suggest that greater levels of hypoxia are required to induce the deleterious morphological changes and  $K^+$  transport activities in red cells from HbSC patients compared to those from HbSS.

Overall, sickling and activation of conductive  $K^+$  movement through  $P_{\text{sickle}}$  and Gardos in red cells from HbSC patients followed the well established pattern observed in red cells from homozygous HbSS patients (Joiner et al., 1993; Lew and Bookchin, 2005; Gibson, 2001). Levels of  $K^+$  movement through the two channels, however, were

significantly reduced in HbSC red cells, consistent with reduced participation of these transport systems in mediating solute loss and red cell dehydration.

### 3.2. Activity and Regulation of the KCl Cotransporter in Red Cells From HbSC and HbSS Patients

Activity of the third transporter, KCC, mediating the obligatorily coupled movement of  $K^+$  and  $Cl^-$ , was also studied. In red cells from HbSC patients, KCC activity was  $0.77 \pm 0.54$  ( $n = 3$ ),  $1.76 \pm 0.26$  ( $n = 6$ ) and  $0.44 \pm 0.23 \text{ mmol} \cdot (\text{l cell} \cdot \text{h})^{-1}$  ( $n = 6$ ) at saline pHs of 6.5, 7.0 and 7.4, and therefore showed a similar bell-shaped relationship to that seen in red cells from HbSS patients (Brugnara et al., 1986). Hypotonicity (265 mOsm cf. 295 mOsm) also increased KCC activity ( $1.26 \pm 0.4 \text{ mmol} \cdot (\text{l cell} \cdot \text{h})^{-1}$  in hypotonic saline cf.  $0.44 \pm 0.23$  in isotonic,  $n = 6$ ) with the effects of hypotonicity and KCC peak activity at pH 7.0 being additive ( $2.76 \pm 0.38 \text{ mmol} \cdot (\text{l cell} \cdot \text{h})^{-1}$ ,  $n = 6$ ). The combined stimulus of low pH and swelling was selected for subsequent experiments.

In the next series of experiments, the  $O_2$  dependence of KCC activity was investigated. In the case of red cells from HbSC patients, activity of KCC was highest in fully oxygenated red cells. As  $O_2$  tension was reduced, KCC activity also fell, showing a reciprocal response to that of sickling and activation of  $P_{\text{sickle}}$  and Gardos channel (Fig. 6 cf. Fig. 2a). In this respect, its behaviour was like that of the transporter in red cells from normal HbAA individuals (Gibson et al., 1998) – although at a considerably higher magnitude overall (Hall and Ellory, 1986). By contrast, in HbSS red cells, although KCC activity initially reduces with  $O_2$  tension, it reaches minimal activity at about the  $P_{50}$  of Hb. It then usually increases again, or remains stable, but does not fall further (Gibson et al., 1998; Hannemann et al., 2014). The  $O_2$  dependence of KCC in HbSC and HbSS are thus markedly different.

A summary of KCC activity in fully oxygenated ( $KCC_{100}$ ) and deoxygenated ( $KCC_0$ ) red cells from HbSC and HbSS patients is presented in Fig. 7a. The difference in  $O_2$  dependence of KCC activity in red cells from the two genotypes is emphasised, with KCC activity higher in oxygenated red cells from HbSC patients than those from HbSS individuals ( $3.42 \pm 0.79 \text{ mmol} \cdot (\text{l cell} \cdot \text{h})^{-1}$ ,  $n = 110$ , in HbSC cf.  $2.74 \pm 0.16 \text{ mmol} \cdot (\text{l cell} \cdot \text{h})^{-1}$ ,  $n = 40$ , in HbSS;  $p = 0.039$ ), with the opposite pattern being observed under deoxygenated conditions ( $0.79 \pm 0.06$  in HbSC cf.  $1.96 \pm 0.21$  in HbSS;  $p < 0.0001$ ). As well as being significantly higher in oxygenated red cells from HbSC patients, KCC activity was markedly variable between HbSC patients, with a lowest value of  $0.44 \text{ mmol} \cdot (\text{l cell} \cdot \text{h})^{-1}$  and highest of 7.61. Therefore red cells from some HbSC individuals have particularly high levels of KCC activity, others present with more modest levels. KCC correlated positively with age in both genotypes, especially in  $KCC_0$  in red cells from HbSC patients ( $r = 0.614$ ,  $p < 0.0001$ ). Functionally, KCC mediates volume decrease in reticulocytes during red cell maturation and diminishes with red cell age (Hall and Ellory, 1986) and reticulocyte % correlated to  $KCC_{100}$  ( $r = 0.540$ ,  $p < 0.0001$ ) and  $KCC_0$  ( $r = 0.28$ ,  $p < 0.0032$ ) in HbSC patients.

Increased cell volume is a well known stimulus for KCC activity (Gibson and Ellory, 2003). In normal individuals, younger red cells and reticulocytes are generally larger, less dense and also show higher levels of KCC activity (Hall and Ellory, 1986). Similarly, the least dense red cells from HbSS patients are enriched for reticulocytes and also for higher levels of KCC activity (Brugnara et al., 1986). This occurs despite the existence of so-called “fast-track” dehydrating reticulocytes (Bookchin et al., 1991). The density distribution of red cells in HbSC patients differs. Thus the percentage of reticulocytes in HbSC patients is greater in the denser fractions (Lawrence et al., 1991). In the final set of experiments, therefore, the total red cell populations were separated on a density gradient into dense and light fractions, each containing about a third of the total red cell population, and KCC activity measured in both fractions. In red cells from HbSS patients, KCC activity was higher in the lighter, more swollen fraction of red cells than in the





Fig. 3. A comparison of  $P_{\text{sickle}}$  activity and sickling in red cells from HbSS and HbSC patients. Red cells were treated as described in the legend to Fig. 2. (a)  $K^+$  influx in  $Cl^-$  free saline in the presence of ouabain (100  $\mu\text{M}$ ), bumetanide (10  $\mu\text{M}$ ) and CLT (5  $\mu\text{M}$ ).  $P_{\text{sickle}}$  activity is calculated as the difference in  $K^+$  influx at 0 and 100 mmHg. (b) Sickling (%). Histograms represent means  $\pm$  S.E.M.,  $n = 110$  for HbSC patients and  $n = 40$  for HbSS. \*\*\*  $p < 0.001$ .



**Fig. 4.** A comparison of Gardos channel activity in red cells from HbSS and HbSC patients. Red cells were treated as described in the legend to Fig. 2. (a) Gardos channel activity (CLT-sensitive  $K^+$  influx in the presence of 100  $\mu$ M ouabain and 10  $\mu$ M bumetanide) in fully oxygenated and fully deoxygenated red cells. Histograms represent means  $\pm$  S.E.M.,  $n = 110$  for HbSC patients and  $n = 40$  for HbSS. \*\*\* $p < 0.001$ . (b) Pearson correlation between  $P_{sickle}$  and Gardos channel in HbSS and HbSC patients. Insert shows a higher resolution at lower magnitudes of activity of  $P_{sickle}$  and Gardos channel. Correlations were calculated as  $r = 0.433$  ( $p < 0.001$ ) for HbSC red cells and  $r = 0.530$  ( $p < 0.001$ ) for HbSS.


denser one (Fig. 8), as expected. The opposite relationship was observed for red cells from HbSC patients such that, in this case, the denser fraction had greater KCC activity. Red cells from the two density fractions will differ in volume, which will affect the activity of a volume-sensitive transport system like KCC. The two fractions were therefore treated with nystatin prior to measurement of KCC activity, so that both had the same initial volume and intracellular cation content. Following nystatin treatment, the higher levels of KCC activity in the denser fraction of red cells from HbSC patients became more exaggerated. These results are consistent with the postulate that denser circulating red cells in HbSC patients have higher levels of KCC activity.

The above findings are consistent with a more prominent role for KCC in solute loss, dehydration and shrinkage in red cells from HbSC patients – which could explain the correlation between disease severity


and KCC activity in this group of patients. By contrast, the conductive  $K^+$  pathways represented by  $P_{sickle}$  and the Gardos channel would appear to be more involved in dehydration of red cells from SCA patients.

**4. Discussion**


The present findings show significant differences in cation homeostasis comparing red cells from HbSC and HbSS patients. The sickling shape change occurred at higher levels of  $O_2$  tension in red cells from HbSS than HbSC patients, together with activation of the main conductive cation channels,  $P_{sickle}$  and the Gardos channel. Both transport pathways showed a similar correlation with sickling. The level of activity of the two channels was significantly lower in HbSC cells compared to HbSS ones, and also required more profound hypoxia to become activated, consistent with a reduced participation of these systems in mediating solute loss and dehydration. By contrast, KCC activity was significantly higher in oxygenated red cells from HbSC patients than those from HbSS individuals. KCC activity varied considerably between



**Fig. 5.** Oxygen dependence of sickling and conductive  $K^+$  pathways in red cells from HbSS and HbSC patients. Red cells were treated as described in the legend to Fig. 2. Sickling (%), and  $P_{sickle}$  and Gardos activities ( $\text{mmol} \cdot (\text{l cells} \cdot \text{h})^{-1}$ ), were normalised to values measured at 0 mmHg (which were  $75 \pm 5\%$ ,  $0.43 \pm 0.06 \text{ mmol} \cdot (\text{l cells} \cdot \text{h})^{-1}$  and  $1.72 \pm 0.47 \text{ mmol} \cdot (\text{l cells} \cdot \text{h})^{-1}$ , respectively, for red cells from HbSC patients; and  $80 \pm 2\%$ ,  $0.82 \pm 0.11 \text{ mmol} \cdot (\text{l cells} \cdot \text{h})^{-1}$ ,  $3.20 \pm 0.47 \text{ mmol} \cdot (\text{l cells} \cdot \text{h})^{-1}$  for red cells from HbSS patients. Histograms represent means  $\pm$  S.E.M.,  $n = 6-8$  for HbSC patients and  $n = 9-12$  for HbSS patients. \*\* $p < 0.01$ , \*\*\*  $< 0.001$  HbSC cf. HbSS.



**Fig. 6.** A comparison of the oxygen dependence of KCl cotransport (KCC) activity, with that of sickling,  $P_{sickle}$  and Gardos activities, in red cells from HbSC patients. Red cells were treated as described in the legend to Fig. 2. KCC activity was measured as the  $\text{Cl}^-$ -dependent  $K^+$  influx in the presence of ouabain (100  $\mu$ M), bumetanide (10  $\mu$ M) and CLT (5  $\mu$ M), and normalised to that measured at 100 mmHg  $O_2$  ( $2.70 \pm 0.58 \text{ mmol} \cdot (\text{l cells} \cdot \text{h})^{-1}$ ,  $n = 4$ ). Percentage sickling and the activities of  $P_{sickle}$  and Gardos channel were normalised to values measured at 0 mmHg ( $75 \pm 5\%$  for sickling;  $0.43 \pm 0.06 \text{ mmol} \cdot (\text{l cells} \cdot \text{h})^{-1}$  and  $1.72 \pm 0.47$ , for  $P_{sickle}$  and Gardos channel, respectively). Data are presented as means  $\pm$  S.E.M.



**Fig. 7.** KCC activity in red cells from HbSC and HbSS patients. Red cells were treated as described in the legends to Fig. 2. (a)  $\text{Cl}^-$  dependent  $\text{K}^+$  influx in the presence of ouabain (100  $\mu\text{M}$ ), bumetanide (10  $\mu\text{M}$ ) and CLT (5  $\mu\text{M}$ ). Histograms represent means  $\pm$  S.E.M.,  $n = 110$  for HbSC patients, and  $n = 40$  for HbSS, \* $p < 0.05$ , \*\*\* $p < 0.001$ . (b) Pearson correlation between KCC activity and age in red cells from HbSC patients. Correlations were calculated as  $r = 0.339$  ( $p < 0.001$ ) at 100 mmHg  $\text{O}_2$  and  $r = 0.614$  ( $p < 0.001$ ) at 0 mmHg.


HbSC individuals. It also showed a different relationship to  $\text{O}_2$  tension to that observed in red cells from HbSS patients, being inactivated at low  $\text{O}_2$  tension (as seen in normal HbAA red cells). There was a higher level of activity of KCC in denser HbSC red cells compared to that observed in lighter ones. Taken together, these findings are consistent with a greater role for KCC in dehydration of red cells from HbSC patients. They also present a characteristic of red cell membrane transport in HbSC patients which may be important in pathogenesis, and further substantiate the hypothesis that HbSC disease is a different entity to that of homozygous HbSS SCD.

Polymerisation of HbS initiates the clinical complications of SCD (Bunn and Forget, 1986). The resulting sequelae are multiple and diverse, and their individual impact on pathogenesis is difficult to elucidate. Early changes include altered red cell membrane permeability (Gibson and Ellory, 2002; Lew and Bookchin, 2005; Tosteson, 1955; Joiner, 1993). That red cells from SCD patients have elevated cation permeability, which can contribute to disease by mediating solute loss, dehydration and raised HbS concentration, has been established for some time (Tosteson, 1955). The reduced lag time to polymerisation upon deoxygenation observed in shrunken red cells with elevated [HbS] is considered central to disease progression (Eaton and Hofrichter, 1987).

Previous reports of cation transport in red cells from HbSC patients have been published but studies were limited to a very small number of individuals (Canessa et al., 1986; Olivieri et al., 1992; Gibson et al., 2001). The present work investigates the behaviour of red cell samples from over a hundred HbSC patients. Of the three transporters involved in dehydration (Lew and Bookchin, 2005), the present findings are consistent with a lesser role for  $\text{P}_{\text{sickle}}$  and Gardos in HbSC disease, whilst supporting a greater involvement of KCC activity (Table 1). The observation that KCC activity in red cells from HbSC patients correlates with frequency of hospitalisation (Rees et al., 2015), a marker of disease severity, emphasises the importance of understanding in detail how this transporter is regulated.

The molecular identity of KCC has been established with four isoforms identified to date, of which three (KCC1, 3 and 4) are found in red cells (Gillen et al., 1996; Pellegrino et al., 1998). In addition, splice variants do occur (Crable et al., 2005), which may be relevant to the different behaviour of KCC in red cells from HbSS and HbSC patients. Physiological regulation of KCC is also complex (Gibson and Ellory, 2003), with evidence for cascades of protein kinases and phosphatases (Cossins et al., 1994), acting on both serine–threonine and tyrosine residues, impacting on transporter activity. This enzymatic regulation is probably key to the differences in response to  $\text{O}_2$  (Gibson et al., 1994; Merciris et al., 2001), perhaps interacting with Hb at the level of the red cell membrane (Sega et al., 2012, 2015). This aspect, however, remains to be fully elucidated.

Maintaining red cell hydration would reduce some of the complications of SCD through reducing the tendency for HbS to polymerise, and represents a longstanding clinical goal (eg Rosa et al., 1980). This is particularly so in red cells from HbSC patients, in which HbS comprises roughly only 50% of the total intracellular Hb. Hydration of these cells would require only a modest increase to reduce the tendency of HbS to polymerise (Fabry et al., 1982). Again, most work has been carried



**Fig. 8.** KCC activity in density separated red cell fractions from HbSS and HbSC patients. Red cells were density separated using OptiPrep gradients and either kept on ice or treated with nystatin. They then were suspended at 20% Hct in  $\text{Cl}^-$  free saline before being diluted 10-fold into test tubes for measurement of  $\text{K}^+$  influx. KCC was measured as  $\text{Cl}^-$  dependent  $\text{K}^+$  influx in the presence of ouabain (100  $\mu\text{M}$ ), bumetanide (10  $\mu\text{M}$ ) and CLT (5  $\mu\text{M}$ ). (a) HbSS red cells. (b) HbSC red cells. Histograms represent means  $\pm$  S.E.M.,  $n = 6$ . \* $p < 0.05$ , \*\* $p < 0.01$  comparing KCC activity in light and dense fractions.

**Table 1**

A comparison of sickling and the main potassium permeability pathways in red cells from patients homozygous (HbSS) or heterozygous (HbSC) for sickle cell disease. See text for detailed explanations.

Sickling	Similar in both genotypes
$\text{P}_{\text{sickle}}$	Reduced in HbSC
Gardos	Reduced in HbSC
KCl cotransport (KCC)	Increased in HbSC
$\text{O}_2$ dependence of KCC	Increased in HbSC
Density dependence of KCC	Higher in denser HbSC red cells Higher in lighter HbSS red cells



out on red cells from homozygous HbSS patients. To date, the most successful strategy has been identification of reagents which inhibit the Gardos channel. Clotrimazole (Ellory et al., 1992), the *in vitro* inhibitor employed in the current study, cannot be used clinically, as its imidazole ring appears to cause hepatopathy (Brugnara et al., 1996). Analogues such as ICA-17,043 (“senicapoc”) have progressed to clinical trials and were successful at increasing red cell hydration in SCD patients (Stocker et al., 2003; Ataga et al., 2008, 2011). Their use has been discontinued as they were unable to reduce pain episodes. Partial  $P_{\text{sickle}}$  inhibitors also exist. They include anion exchange inhibitors such as the stilbenes (Joiner, 1990), but the use of such compounds is precluded by the wide distribution of these transporters through body tissues. Dipyridamole, which is used clinically as an anti-thrombotic compound, also partially reduces  $P_{\text{sickle}}$  activity (Joiner et al., 2001), and has had some success at reducing clinical signs of SCD (Chaplin et al., 1980; Wun et al., 2013).

No specific inhibitor of KCC has progressed to clinical trials, however, although compounds like H74 were shown to specifically target KCC over the related  $\text{Na}^+ - \text{K}^+ - 2\text{Cl}^-$  cotransporter (NKCC) (Ellory et al., 1990). This molecule, or its related analogues, represent compounds of promise. Simple  $\text{Mg}^{2+}$  supplementation has also been used in limited clinical trials, as elevated red cell  $\text{Mg}^{2+}$  inhibits KCC activity, with some success (De Franceschi et al., 1997; De Franceschi et al., 2000). If KCC activity is implicated as a key mechanism in pathogenesis, of particular importance in HbSC patients, re-evaluation of potential KCC inhibitors is warranted.

An alternative approach has involved the development of compounds that directly interpolate with HbS molecules, to increase oxygen affinity and to reduce polymerisation upon deoxygenation. Aromatic aldehydes have shown promise and one of them, 5-hydroxymethyl-2-furfural (5HMF), is currently in phase II clinical trials in SCD patients in the US and UK (Abdulmalik et al., 2005; Stern et al., 2012; Health NIH, 2013; Safo and Kato, 2014). We have recently shown that it has additional effects on  $\text{K}^+$  transport, with inhibition of  $P_{\text{sickle}}$  and Gardos channel and increased hydration, in red cells from SCD patients (Hannemann et al., 2014).

Finally, the marked variability in KCC activity between patients suggests differences of clinical significance in the genetic and molecular control of the transporter when comparing different HbSC individuals. Elucidation of these factors could provide the twin advantages of informing drug design (to inhibit KCC, increase red cell hydration and ameliorate the more severe complications of the disease) and also the possible identification of effective prognostic markers (to inform the management of HbSC patients at an early stage).

## Acknowledgements

The authors are very grateful to the Medical Research Council and Action Medical Research for financial support.

## Authors' Contributions

JSG and DCR designed the study; ST and AH collected samples and carried out experimental work; AH analysed the data; JSG, DCR and AH prepared the manuscript.

## Declaration of Interests

There are no conflicts of interest.

## References

Abdulmalik, O., Safo, M.K., Chen, Q., Yang, J., Brugnara, C., Ohene-Frempong, K., et al., 2005. 5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells. *Br. J. Haematol.* 128, 552–561.

Ataga, K.I., Smith, W.R., De Castro, L.M., Swerdlow, P., Sauntharajah, Y., Castro, O., et al., 2008. Efficacy and safety of the Gardos channel blocker, senicapoc (Ica-17043), in patients with sickle cell anemia. *Blood* 111, 3991–3997.

Ataga, K.I., Reid, M., Ballas, S.K., Yasin, Z., Bigelow, C., St. James, L., et al., 2011. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomised, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043). *Br. J. Haematol.* 153, 92–104.

Bookchin, R.M., Ortiz, O.E., Lew, V.L., 1991. Evidence for a direct reticulocyte origin of dense red cells in sickle cell anemia. *J. Clin. Invest.* 87, 113–124.

Brugnara, C., Bunn, H.F., Tosteson, D.C., 1986. Regulation of erythrocyte cation and water content in sickle cell anemia. *Science* 232, 388–390.

Brugnara, C., Gee, B., Armsby, C.C., Kurth, S., Sakamoto, M., Rifai, N., et al., 1996. Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease. *J. Clin. Invest.* 97, 1227–1234.

Bunn, H.F., Forget, B.G., 1986. *Hemoglobin: Molecular, Genetic and Clinical Aspects*. Saunders, Philadelphia.

Canessa, M., Spalvins, A., Nagel, R.L., 1986. Volume-dependent and NEM-stimulated  $\text{K}^+ - \text{Cl}^-$  transport is elevated in oxygenated SS, SC and CC human red cells. *FEBS Lett.* 200 (1), 197–202.

Chaplin, H.J., Alkjaersig, N., Fletcher, A.P., Michael, J.M., Joist, J.H., 1980. Aspirin-Dipyridamole prophylaxis of sickle cell disease pain crises. *Thromb. Haemost.* 43, 218–221.

Condon, P.I., Serjeant, G.R., 1970. Ocular findings in hemoglobin sc disease in Jamaica. *Am. J. Ophthalmol.* 74, 921–931.

Cossins, A.R., Weaver, Y.R., Lykkeboe, G., Nielsen, O.B., 1994. Role of protein phosphorylation in control of K flux pathways of trout red blood cells. *Am. J. Physiol.* 267, C1641–C1650.

Crable, S.C., Hammond, S.M., Papes, R., Rettig, R.K., Zhou, G.-P., Gallagher, P.G., et al., 2005. Multiple isoforms of the KCl cotransporter are expressed in sickle and normal erythroid cells. *Exp. Hematol.* 33, 624–631.

De Franceschi, L., Bachir, D., Galacteros, F., Tchernia, G., Cynober, T., Alper, S., et al., 1997. Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease. *J. Clin. Invest.* 100, 1847–1852.

De Franceschi, L., Bachir, D., Galacteros, F., Tchernia, G., Cynober, T., Neuberger, D., et al., 2000. Oral magnesium pidolate: effects of long-term administration in patients with sickle cell disease. *Br. J. Haematol.* 108, 284–289.

Delpire, E., Lauf, P.K., 1991. Magnesium and ATP Dependence of K-Cl co-transport in low  $\text{K}^+$ -sheep red blood cells. *J. Physiol.* 441, 219–231.

Dunham, P.B., Ellory, J.C., 1981. Passive potassium transport in low potassium sheep red cells: dependence upon cell volume and chloride. *J. Physiol.* 318, 511–530.

Eaton, J.W., Hofrichter, J., 1987. Hemoglobin S gelation and sickle cell disease. *Blood* 70, 1245–1266.

Ellory, J.C., Dunham, P.B., Logue, P.J., Stewart, G.W., 1982. Anion-dependent cation transport in erythrocytes. *Philos. Trans. R. Soc. Lond. B* 299, 483–495.

Ellory, J.C., Hall, A.C., Ody, S.O., Englert, H.C., Mania, D., Lang, H.-J., 1990. Selective inhibitors of KCl cotransport in human red cells. *FEBS Lett.* 262 (2), 215–218.

Ellory, J.C., Culliford, S., Stone, P.C.W., Stuart, J., 1992. Clotrimazole, a potent gardos channel inhibitor, protects sickle cells from K loss and dehydration. *J. Physiol.* 159P.

Fabry, M.E., Harrington, J., Chang, H., Nagel, R.L., 1982. Critical contribution of cell density to the pathophysiology of SC cells. *Clin. Res.* 30, 559a.

Gibson, J.S., 2001. Oxygen-sensitive cation transport in sickle cells. *Blood Cells Mol. Dis.* 27, 112–120.

Gibson, J.S., Ellory, J.C., 2002. Membrane transport in sickle cell disease. *Blood Cells Mol. Dis.* 28, 1–12.

Gibson, J.S., Ellory, J.C., 2003.  $\text{K}^+ - \text{Cl}^-$  cotransport in vertebrate red cells. In: Bernhardt, I., Ellory, J.C. (Eds.), *Red Cell Membrane Transport in Health and Disease*. Springer Verlag, Berlin, pp. 197–220.

Gibson, J.S., Honess, N.A., Cossins, A.R., Ellory, J.C., Schwabe, A.E., 1994. Oxygen tension and KCl co-transport in equine red cells. *J. Physiol.* 476.P (60 pp.).

Gibson, J.S., Speake, P.F., Ellory, J.C., 1998. Differential oxygen sensitivity of the  $\text{K}^+ - \text{Cl}^-$  cotransporter in normal and sickle human red blood cells. *J. Physiol.* 511, 225–234.

Gibson, J.S., Muzyamba, M.C., Ball, S.E., Ellory, J.C., 2001.  $\text{K}^+$  transport in HbSC-containing human red blood cells. *J. Physiol.* 535P (27 pp.).

Gillen, C.M., Brill, S., Payne, J.A., Forbusch, I.B., 1996. Molecular cloning and functional expression of the KCl cotransporter from rabbit, rat and human. *J. Biol. Chem.* 271, 16237–16244.

Hall, A.C., Ellory, J.C., 1986. Evidence for the Presence of volume-sensitive KCl transport in ‘young’ human red cells. *Biochim. Biophys. Acta* 858, 317–320.

Hannemann, A., Cytlak, U.M., Wilkins, R.J., Ellory, J.C., Rees, D.C., Gibson, J.S., 2011. The use of radioisotopes to characterise the abnormal permeability of red blood cells from sickle cell patients. In: Singh, N. (Ed.), *Radioisotopes: Applications in Bio-Medical Science*. InTech, Rijeka, pp. 151–172.

Hannemann, A., Cytlak, U.M., Rees, D.C., Tewari, S., Gibson, J.S., 2014. Effects of 5-hydroxymethyl-2-furfural on the volume and membrane permeability of red blood cells from patients with sickle cell disease. *J. Physiol.* 592, 4039–4049.

Health NIH, 2013. Evaluation of different dose regimens of Aes-103 given for 28 days to subjects with stable sickle cell disease. <http://www.clinicaltrials.gov/ct2/show/NCT01987908/>.

Joiner, C.H., 1990. Deoxygenation-induced cation fluxes in sickle cells: II. Inhibition by stilbene disulfonates. *Blood* 76, 212–220.

Joiner, C.H., 1993. Cation transport and volume regulation in sickle red blood cells. *Am. J. Physiol.* 264, C251–C270.

- Joiner, C.H., Morris, C.L., Cooper, E.S., 1993. Deoxygenation-induced cation fluxes in sickle cells. III. Cation selectivity and response to pH and membrane potential. *Am. J. Physiol.* 264, C734–C744.
- Joiner, C.H., Jiang, M., Claussen, W.J., Roszell, N.J., Yasin, Z., Franco, R.S., 2001. Dipyridamole inhibits sickling-induced cation fluxes in sickle red blood cells. *Blood* 97, 3976–3983.
- Joyce, C.R.B., 1958. Uptake of potassium by parts of packed human blood cell column. *Q. J. Exp. Physiol.* 43, 299–309.
- Lauf, P.K., Bauer, J., Adragna, N.C., Fujise, H., Martin, A., Zade-Oppen, M., et al., 1992. Erythrocyte K-Cl cotransport: properties and regulation. *Am. J. Physiol.* 263, C917–C932.
- Lawrence, C., Fabry, M.E., Nagel, R.L., 1991. The unique red cell heterogeneity of SCD disease: crystal formation, dense reticulocytes and unusual morphology. *Blood* 78, 2104–2112.
- Lew, V.L., Bookchin, R.M., 2005. Ion transport pathology in the mechanism of sickle cell dehydration. *Physiol. Rev.* 85, 179–200.
- Lew, V.L., Ortiz, O.E., Bookchin, R.M., 1997. Stochastic nature and red cell population distribution of the sickling-induced  $\text{Ca}^{2+}$  permeability. *J. Clin. Invest.* 99 (11), 2727–2735.
- Merciris, P., Hardy-Dessources, M.D., Giraud, F., 2001. Deoxygenation of sickle cells stimulates Syk tyrosine kinase and inhibits a membrane tyrosine phosphatase. *Blood* 98, 3121–3127.
- Mohandas, N., Rossi, M.E., Clark, M.R., 1986. Association between morphologic distortion of sickle cells and deoxygenation-induced cation permeability increases. *Blood* 68, 450–454.
- Nagel, R.L., Lawrence, C., 1991. The distinct pathobiology of sickle cell-hemoglobin C disease. Therapeutic implications. *Hematol. Oncol. Clin. North Am.* 5, 433–451.
- Nagel, R.L., Platt, O.S., 2001. General pathophysiology of sickle cell anemia. In: Steinberg, M.H., Forget, B.G., Higgs, D.R., Nagel, R.L. (Eds.), *Disorders of Hemoglobin*. Cambridge University Press, Cambridge, pp. 494–526.
- Nagel, R.L., Steinberg, M.H., 2001. Hemoglobin SC disease and HbC disorders. In: Steinberg, M.H., Forget, B.G., Higgs, D.R., Nagel, R.L. (Eds.), *Disorders of Hemoglobin*. Cambridge University Press, Cambridge, pp. 756–785.
- Nagel, R.L., Fabry, M.E., Steinberg, M.H., 2003. The paradox of hemoglobin SC disease. *Blood Rev.* 17, 167–178.
- Olivieri, O., Vitoux, D., Galacteros, F., Bachir, D., Blouquit, Y., Beuzard, Y., et al., 1992. Hemoglobin variants and activity of ( $\text{K}^+ \text{Cl}^-$ ) cotransport system in human erythrocytes. *Blood* 79, 793–797.
- Ortiz, O.E., Lew, V.L., Bookchin, R.M., 1990. Deoxygenation permeabilizes sickle cell anaemia red cells to magnesium and reverses its gradient in the dense cells. *J. Physiol.* 427, 211–226.
- Pellegrino, C.M., Rybicki, A.C., Musto, S., Nagel, R.L., Schwartz, R.S., 1998. Molecular identification of erythroid K:Cl cotransporter in human and mouse erythroleukemic cells. *Blood Cells Mol. Dis.* 24, 31–40.
- Piel, F.B., Patil, A.P., Howes, R.E., Nyangiri, O.A., Gething, P.W., Dewi, M., et al., 2013. Global Epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. *Lancet* 381, 142–151.
- Platt, O.S., Thorington, B.D., Brambilla, D.J., Milner, P.F.A., Rosse, W.F., Vichinsky, E., et al., 1991. Pain in sickle cell disease. Rates and risk factors. *N. Engl. J. Med.* 325, 11–16.
- Platt, O.S., Brambilla, D.J., Rosse, W.F., et al., 1994. Mortality in Sickle cell disease: life expectancy and risk factors for early death. *N. Engl. J. Med.* 330, 1639–1644.
- Rees, D.C., Williams, T.N., Gladwin, M.T., 2010. Sickle-cell disease. *Lancet* 376, 2018–2031.
- Rees, D.C., Thein, S.L., Osei, A., Drasar, E., Tewari, S., Hannemann, A., et al., 2015. The clinical significance of KCl cotransport activity in red cells of patients with HbSC disease. *Haematologica* (in press).
- Rhoda, M.D., Apovo, M., Beuzard, Y., Giraud, F., 1990.  $\text{Ca}^{2+}$  permeability in deoxygenated sickle cells. *Blood* 75, 2453–2458.
- Rosa, R., Bierer, B.A., Thomas, R., Stoff, J.S., Kruskall, M., Robinson, S., et al., 1980. A study of hyponatremia in the prevention and treatment of sickle-cell crisis. *N. Engl. J. Med.* 303, 1138–1143.
- Safo, M.K., Kato, G.J., 2014. Therapeutic strategies to alter oxygen affinity of sickle hemoglobin. *Hematol. Oncol. Clin. North Am.* 28, 217–231.
- Sega, M.F., Chu, H., Christian, J.A., Low, P.S., 2012. Interaction of deoxyhemoglobin with the cytoplasmic domain of murine erythrocyte band 3. *Biochemistry* 51, 3264–3272.
- Sega, M.F., Chu, H., Christian, J.A., Low, P.S., 2015. Fluorescence assay of the interaction between hemoglobin and the cytoplasmic domain of erythrocyte membrane band 3. *Blood Cells Mol. Dis.* 55, 266–271.
- Speake, P.F., Roberts, C.A., Gibson, J.S., 1997. Effect of changes in respiratory blood parameters on equine red blood cell K-Cl cotransporter. *Am. J. Physiol.* 273, C1811–C1818.
- Steinberg, M.H., Forget, B.G., Higgs, D.R., Nagel, R.L. (Eds.), 2001. *Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management*. Cambridge University Press, Cambridge.
- Stern, W., Matthews, D., McKew, J.C., Shen, J., Kato, G.J., 2012. A phase 1, first-in-man, dose-response study of Aes-103 (5-HMF), an anti-sickling, allosteric modifier of hemoglobin oxygen affinity in healthy normal volunteers. *Am. Soc. Hematol. 54th Annual meeting (Atlanta)*, 3210.
- Stocker, J.W., De Franceschi, L.D., McNaughton-Smith, G.A., Corrocher, R., Beuzard, Y., Brugnara, C., 2003. ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. *Blood* 101, 2412–2418.
- Tosteson, D.C., 1955. The Effects of sickling on ion transport. II. The effect of sickling on sodium and cesium transport. *J. Gen. Physiol.* 39, 55–67.
- Tosteson, D.C., Shea, E., Darling, R.C., 1952. Potassium and sodium of red blood cells in sickle cell anaemia. *J. Clin. Invest.* 48, 406–411.
- Wun, T., Soulieres, D., Frelinger, A.L., Krishnamurti, L., Novelli, E.M., Kutlar, A., et al., 2013. A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. *J. Hematol. Oncol.* 6, 17–26.